Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 2/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754480 | 0.80 | NUDT1 (0.61) | NUDT1POLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7052094 | 0.77 | KMT2A (0.42) | NUDT1POLBCYP1A2CYP2C19CYP2C9 | |
| SCHEMBL151114 | 0.75 | — | — | |
| SCHEMBL15498159 | 0.75 | NUDT1 (0.61) | NUDT1POLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL18134205 | 0.75 | NUDT1 (0.66) | NUDT1POLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL8795406 | 0.75 | NUDT1 (0.51) | NUDT1POLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL8629598 | 0.74 | CYP1A2 (0.50) | NUDT1POLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL14879957 | 0.74 | NUDT1 (0.54) | NUDT1POLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL12074772 | 0.74 | NUDT1 (0.64) | NUDT1POLBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL11170200 | 0.74 | NUDT1 (0.58) | NUDT1POLBSMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346878-B1 | FUSED PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-01 | — | — | EP | disclosed |
| US-8653272-B2 | Fused pyridine derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2014-02-18 | — | — | US | disclosed |
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110201630-A1 | Fused Pyridine Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2011-08-18 | — | — | US | disclosed |
| EP-2346878-A1 | FUSED PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2011-07-27 | — | — | EP | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
| EP-2231641-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010061180-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010046639-A1 | FUSED PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-04-29 | — | — | WO | disclosed |
| WO-2009081105-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | NUDT1 1761/4885POLB 1450/4885SMN1; SMN2 3405/4885 |
| US-20110201630-A1 | Fused Pyridine Derivatives as Kinase Inhibitors | MAP2K2, MAP4K2, MAP3K6 | NUDT1 2633/4885POLB 1595/4885SMN1; SMN2 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.